Actelion Pharmaceuticals – Patrick Sieber

We use this innovative technology to characterize advanced compounds, but also to confirm screening hits and to prioritize between chemical lead classes. We use the Monolith NT.115 from NanoTemper Technologies to determine binding affinities and expand its application range to thermodynamic characterizations…We observe a very good agreement of MST to other biophysical methods like surface plasmon resonance, X-ray structural information and molecular modeling.


Dr. Patrick Sieber
Lab Head R&D Cardiovascular and Fibrosis Biology
Actelion Pharmaceuticals
Allschwil, Switzerland